Putting the squeeze on pharma pricing in the EU

Approx.
2 min read
Caption:
First Published: 
Nov 2011
Updated: 

Key Learnings contained in this article:

The world is a daily classroom on basic economics principles: from the Greece bailout, to the austerity measures in several EU countries, to debate over the Chinese yuan currency, to the American recession and Occupy Wall Street protests.

Economists on both ends of the political and economic spectra argue vociferously as to why their philosophies make the most sense, only to have history weigh in with confounding factors – pesky details like accounting fraud, war, disease, technology developments, and demographic changes.

A common US case study: how the US emerged from the Great Depression in the 1930s. Was it because of President Roosevelt’s New Deal policies or the socio-economic shifts in industry required by the start of World War II? The debate rages on. What I see, with each discussion, is that the more you try to control an economic system, the more it will contort itself to go where it wants, much like squeezing a water balloon.

Adam Barak, Director of PharmaPrice International (PPi Ltd) provides an amusing yet insightful explanation of pharmaceutical pricing policy in Europe, and how it relates to the prices of other common goods, such as cars…and football viewing. As individual European governments continue to struggle with EU laws, the water balloon will continue to contort.

We'll deliver straight to your inbox

We take your privacy very seriously and will never share your details with other parties.
You're subscribed! We'll send you a welcome email shortly, keep an eye out and if you don't find it perhaps check the (sometimes over-zealous) spam folder.
Oops! Something went wrong while submitting the form.
Mary Gabb
Share this post

Discover the Power of Communication with Rx

Embark on your medcomms journey with Rx today and experience the difference of working with a world-class medical communications agency.

Child playing in autumn leaves
Copyright Rx Communications Ltd